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A significant number of sudden death (SD) is observed in myotonic dystrophy 
(DM1) despite pacemaker implantation and some consider the ICD to be the pref-
erential device in patients with conduction disease. According to the latest guide-
lines, prophylactic ICD implantation in patients with neuromuscular disorder 
should follow the same recommendations of non-ischemic dilated cardiomyopathy, 
being reasonable when pacing is needed. We here report a case of DM1 patient 
who underwent ICD implantation even in the absence of conduction disturbances 
on ECG and ventricular dysfunction/fibrosis at cardiac magnetic resonance. The 
occurrence of syncope, non-sustained ventricular tachycardias at 24-Holter ECG 
monitoring and a family history of SD resulted associated with ventricular fibril-
lation inducibility at electrophysiological study, favouring ICD implantation. On 
our advice, DM1 patient with this association of SD risk factors should be targeted 
for ICD implantation.
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Introduction
Myotonic dystrophy type 1 (DM1) is the most frequent muscular dys-
trophy in adults. Cardiac involvement is reported in about 80% of cases, 
even in asymptomatic patients 1. Conduction system disturbances on sur-
face ECG or ventricular dysfunction are considered the most relevant risk 
factors for sudden cardiac death (SD), favouring pacemaker (PM) implan-
tation according to latest guidelines 2,3. However, recent data showed that 
SD, striking up to one third of patients, can also occur for ventricular tach-
yarrhythmias (VTA) and that other predictive factors like syncope, family 
history of SD or non-sustained VT should be taken into account for risk 
stratification 4. We report the case of a mildly symptomatic DM1 patient 
who underwent ICD implantation for high ventricular vulnerability at the 
electrophysiological evaluation even in the absence of either conduction 
disturbances at ECG or ventricular dysfunction/fibrosis at non-invasive 
evaluation by echocardiogram and cardiac magnetic resonance. 
Case report
A 42 year-old woman, affected by poorly symptomatic DM1 presented 
at our emergency department for syncope and palpitations. She was diag-
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nosed with DM1 three years earlier showing an increased 
CTG repeat length, with a number size defined between 
50-500. The patient showed temporal muscle atrophy, 
proximal weakness at lower limbs and grip and evoked 
myotonia. Needle electromyography (EMG) showed 
mild myopathic changes and myotonic discharges. The 
patient reported a case of SD in her family history (mater-
nal grandmother, at age 29). On arrival at our department 
the vital signs were the following: blood pressure 110/70 
mmHg, peripheral oxygen saturation 99% in room air, 
heart rate 70 bpm. No specific drugs were assumed. Bas-
al surface ECG showed sinus rhythm with a PR interval 
of 0.16 seconds and a QRS duration of 0.10 seconds. A 
recent 24 hours-Holter ECG monitoring recorded 27 ep-
isodes of non-sustained VTs (Fig. 1). Echocardiography 
showed preserved left ventricular (LV) systolic and di-
astolic function (EF 55%). Cardiac magnetic resonance 
(CMR) excluded intramyocardial fibrosis and confirmed 
a preserved biventricular systolic function. Electrophysi-
ological study (EPS) showed normal correct sinus node 
recovery time (CSNRT 420  msec) and atrio-ventricu-
lar node conduction times (AH 84 msec; HV 41 msec) 
(Fig. 2). During ventricular stimulation from right ven-
tricle apex (refractory period: 200 msec with drive of 
600  msec), sustained ventricular fibrillation (VF) was 
easily induced (coupling intervals: 600-240-200  msec) 
and rapidly interrupted with single external DC-Shock. 
EPS was followed by dual chamber transvenous ICD 
implantation. ICD remote home monitoring (Medtronic 
CareLink® System) was provided for VTAs burden sur-
veillance. Low dosage of bisoprolol was started with rap-
id relief from palpitation and dizziness. ACE-inhibitors 
were not started for hypotension. Patient was regularly 
discharged on 7th day from admission. At 1 year of follow 
up, the patient was still asymptomatic on bisoprolol, and 
in good clinical conditions. Remote monitoring showed 
VTAs monthly burden of 0.4%. 
Discussion
Myotonic Dystrophy type  1 is an autosomal, dom-
inant disorder due to CTG expansion in the untranslat-
ed 3’ region of the DM1 protein kinase (DMPK) gene 
and is the most frequent muscular dystrophy in adults 1. 
Cardiac involvement often precedes the muscular/neuro-
logical signs and up to one third of deaths is sudden and 
unexpected, showing that risk stratification is crucial in 
the management of DM1  2. SCD is most likely due to 
high-degree atrioventricular (AV) block; however, ven-
tricular tachyarrhythmias are increasingly recognised as a 
common finding in these patients and might explain some 
cases of sudden death after pacemaker (PM) implanta-
tion  5. Paroxysmal supraventricular tachyarrhythmias 
(atrial fibrillation, atrial flutter, atrial tachycardia) are a 
common finding on electrocardiographic monitoring with 
a prevalence up to 25% in DM1 patients. Atrial fibrilla-
tion/flutter (AF/AFl), a frequent feature in DM1 patients, 
may be the first clinical manifestation of the disease in 
Figure 2. Panel A. basal ECG-Panel B. HV interval at 
electrophysiological study.
Figure 1. NSVT at 24 hour Holter ECG recording.
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young patients and seems to increase the mortality in 
this population.6 Given the high risk of supraventricular 
arrhythmias and their consequences, clinical and instru-
mental strategies for reducing the risk of atrial fibrillation 
are of pivotal importance in the optimization of clinical 
management.
Previous studies showed that abnormalities of 
the conduction system on surface ECG (PR interval  > 
240 msec, QRS interval > 120 msec, left bundle branch 
block) were independent risk factors for SD, presumably 
owing to the progression of conduction system disease 
to a complete atrio-ventricular block  5. Currently, a HV 
interval > 70 msec at EPS is predictive of an appropri-
ate indication for PM implantation in DM1 7. However, 
a significant number of SD is observed, despite the PM 
implantation, and some clinicians consider ICD as the 
preferential device for DM1 patients with conduction dis-
ease 8,9. Myocardial fibrosis at CMR is present in 40% of 
DM1 patients and is not predicted by ECG, ECG-Holter 
monitoring and echocardiography, but is often associat-
ed with increased risk of SD  10. According to the latest 
guidelines, the prophylactic implantation of ICD in pa-
tients with neuromuscular disorders should follow the 
same criteria as in non-ischemic dilated cardiomyopathy, 
so an ICD implantation may be reasonable in DM1 pa-
tients when pacing is needed 2. However, in DM1, VTAs 
may occur even in patients with normal ECG and pre-
served LV systolic function. A recent large study on 1388 
DM1 patients reported a 3.6% cumulative incidence of 
SD over a median 10-year follow-up, with the involve-
ment of multiple mechanisms including conduction 
defects, sustained VTAs and extracardiac causes  4. Ac-
cording to this study, age, male sex, syncope, heart rate 
and 1st degree AV block were independent predictors of 
overall mortality, at a multivariate analysis. Of note, age, 
family history of SD and left bundle brunch block were 
significantly associated with SD. Furthermore, non-sus-
tained VTAs, recorded at Holter ECG monitoring, were 
the only predictors of sustained VTAs 4.
We describe the case of a young woman affected 
by early stage DM1 – with preserved cardiac function 
and absence of conduction abnormalities either at bas-
al surface ECG or EPS evaluation – who needed ICD 
implantation for the presence of syncope, non-sustained 
VTAs at 24-Hour ECG monitoring, and a family history 
of SD associated with a VF inducibility at EPS. The de-
cision for ICD implantation was in accordance with ESC 
Syncope Guidelines. The high ventricular vulnerability 
was not associated with intramyocardial scar or cardi-
ac dysfunction at CMR. In our view, further studies are 
needed and a revision of current recommendations for 
ICD implantation in DM1 could be considered, mostly 
in patients presenting with syncope, non-sustained VTAs 
and a family history of SD. In this subset of patients, 
the evidence of high ventricular vulnerability at EPS, 
rather than cardiac dysfunction or conduction abnormal-
ities, would be useful in identifying subjects eligible for 
ICD implantation to prevent unexpected deaths, whose 
incidence is not negligible. In conclusion, to date, the 
best strategy for SD risk stratification in DM1 patients 
is not yet well known. In addition to Groh criteria (PR 
≥ 240 ms, QRS ≥ 120 ms or atrial tachy-arrhythmias), 
recent evidences showed that age, syncope, family histo-
ry of SCD and left bundle branch block are independent 
predictors of SD. Nevertheless, the role of ICD implan-
tation in DM1 patients with preserved systolic function 
is not fully clarified and the choice of best device to im-
plant is based on patient-centred electrophysiological 
evaluation. Our clinical case confirms the recommenda-
tions that family history of SD, syncope with palpitation 
and non-sustained VTAs may be considered red flags for 
high risk of SD in DM1 patients, even when conduction 
disorders, ventricular dysfunction and CMR ventricular 
fibrosis cannot be detected with conventional instru-
mental investigation. This risk is confirmed by the high 
ventricular vulnerability at the EPS evaluation in these 
patients. Further studies are needed to evaluate if the 
EPS-guided therapy, including the prophylactic ICD im-
plantation in inducible patients, will prevent SD in DM1 
patients without ventricular dysfunction and conduction 
disorders compared with conventional therapy. 
References
1 Petri H, Vissing J, Witting N, et al. Cardiac manifestations of myo-
tonic dystrophy type 1. Int J Cardiol 2012;160:82-8. https://doi.
org/10.1016/j.ijcard.2011.08.037 
2 Priori SG, Blomstro¨m-Lundqvist C, Mazzanti A, et al. 2015 
ESC Guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death: the task 
force for the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death of the European Society 
of Cardiology (ESC). Eur Heart J 2015;36:2793-867. https://doi.
org/10.1093/eurheartj/ehv316
3 Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/
ACC/HRS guideline for management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death: Executive 
summary: A Report of the American College of Cardiology/Amer-
ican Heart Association Task Force on Clinical Practice Guidelines 
and the Heart Rhythm Society. Heart Rhythm 2018;15:e190-252. 
https://doi.org/10.1016/j.hrthm.2017.
4 Wahbi K, Babuty D, Probst V, et al. Incidence and predictors of 
sudden death, major conduction defects and sustained ventricular 
tachyarrhythmias in 1388 patients with myotonic dystrophy type 
1. Eur Heart J 2017;38:751-8. https://doi.org/10.1093/eurheartj/
ehw569
Myotonic dystrophy type 1 and sudden cardiac death predictors 
35
5 Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormal-
ities and sudden death in myotonic dystrophy type 1. N Engl J Med 
2008;358:2688-97. https://doi.org/10.1056/NEJMoa062800
6 Stoyanov N, Winterfield J, Varma N, et al. Atrial arrhythmias in 
the young: early onset atrial arrhythmias preceding a diagnosis of 
a primary muscular dystrophy. Europace 2014;16:1814-20. https://
doi.org/10.1093/europace/euu141 
7 Wahbi K, Meune C, Porcher R, et al. Electrophysiological study 
with prophylactic pacing and survival in adults with myoton-
ic dystrophy and conduction system disease. J Am Med Assoc 
2012;307:1292-301. https://doi.org/10.1001/jama.2012.346
8 Russo V, Nigro G, Politano L. Role of electrophysiological eval-
uation for the best device choice to prevent sudden cardiac death 
in patients with myotonic dystrophy type 1 and emery dreifuss 
muscular dystrophy. Trends Cardiovasc Med 2017. pii: S1050-
1738(17)30013-0. https://doi.org/10.1016/j.tcm.2017.02.001
9 Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardio-
verter-defibrillator use in a US myotonic dystrophy type 1 popula-
tion. J Cardiovasc Electrophysiol 2011;22:1369 -75. https://doi.org
/10.1111/j.1540-8167.2011.02200
10 Petri H, Ahtarovski KA, Vejlstrup N, et al. Myocardial fibrosis in 
patients with myotonic dystrophy type 1: a cardiovascular magnetic 
resonance study. J Cardiovasc Magn Reson 2014;16:59. https://doi.
org/10.1186/s12968-014-0059-z
